

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
12 October 2023 (12.10.2023)



(10) International Publication Number  
**WO 2023/196218 A3**

(51) International Patent Classification:

*A61K 31/505* (2006.01) *A61K 31/135* (2006.01)  
*A61K 31/506* (2006.01) *A61K 31/33* (2006.01)  
*A61K 31/44* (2006.01) *A61K 31/423* (2006.01)

(21) International Application Number:

PCT/US2023/017254

(22) International Filing Date:

03 April 2023 (03.04.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/329,104 08 April 2022 (08.04.2022) US

(71) Applicant: **MIRATI THERAPEUTICS, INC.** [US/US];  
3545 Cray Court, San Diego, CA 92121 (US).

(72) Inventors: **HALING, Jacob**; c/o Mirati Therapeutics, Inc.,  
3545 Cray Court, San Diego, CA 92121 (US). **KHARE,**  
**Shilpi**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San  
Diego, CA 92121 (US).

(74) Agent: **POLYAKOV, Mark, V.** et al.; Wood, Phillips, Katz,  
Clark & Mortimer, 500 West Madison Street, Suite 1130,  
Chicago, IL 60661 (US).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

16 November 2023 (16.11.2023)

WO 2023/196218 A3

(54) Title: COMBINATION THERAPIES COMPRISING A SOS1 INHIBITOR AND A MEK INHIBITOR

(57) Abstract: The present invention relates to combination therapies for treating cancers associated with genetic alterations of the MAPK pathway and/or EGFR. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SOS1 inhibitor and MEK inhibitor, pharmaceutical compositions comprising a such compositions, kits comprising such compositions and methods of use therefor.